Classic long-acting psychedelic; MindMed's MM120 is in Phase 3 for generalized anxiety disorder.
LSD is a semi-synthetic ergoline-class compound acting primarily as a partial agonist at the 5-HT2A receptor — the same receptor target as psilocybin, though with different binding kinetics and a substantially longer duration. A typical oral clinical dose of 100–200 µg produces onset within 30–90 minutes, a plateau over 4–6 hours, and a return to baseline at roughly 10–12 hours.
Historically, LSD was the psychedelic most actively studied in psychiatric research between the mid-1950s and the late 1960s, with thousands of published reports covering alcoholism, anxiety, and end-of-life distress. Schedule I classification in 1970 effectively ended that era. The current renaissance focuses primarily on one pharmaceutical program.
Mind Medicine (MindMed) is developing MM120 (lysergide D-tartrate) as an orally disintegrating tablet (ODT) intended for single-dose administration in-office. The program is the only Phase 3 psychedelic development effort for LSD worldwide.
The 198-patient dose-ranging study (25, 50, 100, 200 µg vs placebo) in generalized anxiety disorder produced the foundational efficacy signal:3
On the strength of those results, the FDA granted MM120 Breakthrough Therapy Designation in March 2024 and MindMed held its End-of-Phase 2 meeting shortly after.1
| Trial | Indication | Design | Expected readout |
|---|---|---|---|
| Voyage (MM120-300) | Generalized anxiety disorder | ~200 US patients, 1:1 MM120 100 µg vs placebo; 12-week double-blind period; HAM-A primary endpoint. | 1H 2026 |
| Panorama (MM120-301) | Generalized anxiety disorder | ~250 patients US + EU, 2:1:2 randomization to 100 µg, 50 µg, placebo — the 50 µg arm is intended to control for functional unblinding. | 2H 2026 |
| Emerge | Major depressive disorder | Phase 3 initiated 2025; 100 µg vs placebo. | 2H 2026 |
Panorama’s additional 50-microgram arm is a deliberate design response to the blinding concerns the FDA raised in its MDMA CRL — by comparing two active doses and a placebo, the study aims to separate subjective "perceptual" effects from genuine therapeutic effect.2
MindMed’s chief medical officer has publicly argued that LSD has several differentiators relative to ketamine and SSRIs as GAD treatments: a single-dose paradigm (versus daily SSRI dosing), a rapid onset (versus weeks for SSRIs), and a large effect size (Phase 2b effect sizes of 0.7–0.8 versus roughly 0.3 for SSRIs). These comparisons are pre-Phase 3 and will be tested directly when Voyage and Panorama read out.
Microdosing — taking ~10–20 µg of LSD (roughly 1/10 of a macrodose) on a schedule such as every third day — is a major internet phenomenon. The self-report literature is full of positive claims around focus, mood, and creativity. The controlled literature is much more sobering.
The most-cited controlled trial is Szigeti et al. (2021) in eLife, which used a "self-blinding" citizen-science protocol with 191 regular microdosers. Over four weeks, all psychological benefits could be attributed to expectancy effects — both the active and placebo arms improved similarly.5 Subsequent controlled work (Aday et al., Bershad et al.) has generally reached the same conclusion: the measurable acute effects of microdoses are small, and durable cognitive or mood benefits are not reliably distinguishable from placebo.
| Dimension | Microdose (~10–20 µg) | Macrodose / therapeutic dose (100–200 µg) |
|---|---|---|
| Subjective experience | "Sub-perceptual" — should not feel high. Users report subtle mood or focus changes. Any visible perceptual effect means the dose is too high. | Strong perceptual changes, emotional intensity, visual phenomena. An 8–12 hour experience; not compatible with normal daily tasks. |
| Controlled evidence | Weak to absent. Best-controlled trial (Szigeti et al., 2021) attributed all benefits to expectancy. Subsequent blinded studies agree. | Moderate and growing. Phase 2b RCT (MMED008) showed significant HAM-A reduction vs. placebo at week 12; Phase 3 trials underway. |
| Dosing schedule | Typically every third day ("Fadiman protocol") or every other day. Proponents rotate to avoid tolerance, though tolerance with sub-perceptual doses is poorly characterized. | One or two sessions, weeks or months apart. The MM120 clinical model is a single dose; many historical protocols used 1–3 doses total. |
| Safety monitoring needed | Low in theory, but chronic frequent exposure raises the same bladder and cardiovascular cautions as any repeated psychedelic use. Data on long-term safety are thin. | Requires supervised clinical setting. Staff present for the full 8–12 hour session. Blood pressure and cardiac monitoring recommended. |
| Legal risk | Same as macrodosing: LSD is Schedule I, possession is a federal felony. Low dose does not lower legal risk. | Same Schedule I risk, but typically administered inside an FDA-regulated trial — the only legal US route. |
| Bottom line | Popular, but controlled evidence does not support the reported benefits over placebo. Risks of frequent unmonitored use are not well-studied. | Backed by the only FDA-quality LSD trial data. The path toward possible FDA approval is built on this model. |
Longer-term considerations:
LSD is Schedule I in the United States — no accepted medical use, research requires FDA IND and DEA Schedule I registration. MM120 holds Breakthrough Therapy Designation, which affects review speed and FDA engagement but does not change the current scheduling. An approved MM120 NDA would ultimately require DEA rescheduling.
LSD is illegal in all 50 states. Unlike psilocybin or DMT, LSD is not included in any state’s decriminalization or therapeutic-access reform:
The honest answer for LSD is uniform, unlike DMT or psilocybin: there is no state anywhere in the US with an LSD-specific decriminalization program, therapeutic-access carve-out, or exemption. The table below names the individual states most often searched by name; all carry the same status.
| State | LSD status | Notes |
|---|---|---|
| Colorado | Schedule I | Prop 122 decriminalizes psilocybin, DMT, ibogaine, and mescaline — LSD is not included. |
| Oregon | Schedule I | Measure 109 licensed services cover psilocybin only; LSD is not part of the program. |
| California | Schedule I | No state decrim passed; city entheogen resolutions target plant/fungi-based substances, not synthetic LSD. |
| Connecticut, Georgia, Hawaii, Massachusetts, Michigan, Minnesota, Missouri, Maryland, Washington, New Jersey, New York, Rhode Island, Texas, Tennessee, Utah, Virginia, Vermont, West Virginia, Wisconsin | Schedule I under both federal and state law | No LSD-specific decriminalization, exemption, or therapeutic program exists in any of these states as of 2026. |
| All other states | Schedule I | Same uniform status: no state has decriminalized or created a therapeutic-access pathway for LSD. |
For a full state-by-state view of all substances, see the psychedelic legal status by US state tool.
LSD is controlled in essentially every country that has ratified the 1971 UN Convention on Psychotropic Substances, which places it at the strictest scheduling tier almost everywhere. A handful of countries have broader decriminalization policies that happen to cover LSD as part of an all-drugs approach, and Switzerland has a narrow physician-led compassionate-use pathway — but no country has legalized or created a general therapeutic-access program for LSD specifically.
| Country | Status | Details |
|---|---|---|
| Switzerland | Compassionate use | LSD is a controlled substance, but Switzerland's limited "compassionate use" scheme has authorized a small number of individual, physician-led LSD-assisted psychotherapy cases since 2014. This is not a general legalization or retreat pathway. |
| Portugal | Decriminalized | Personal possession of all drugs, including LSD, has been decriminalized since 2001 as a public-health measure. Possession of small quantities is an administrative offense; trafficking and supply remain criminal. |
| United Kingdom | Class A | LSD is a Class A drug under the Misuse of Drugs Act 1971 — the UK's strictest category. Possession carries up to 7 years; supply up to life imprisonment. |
| Netherlands | List I | LSD is a List I (hard drugs) controlled substance with no decriminalization precedent comparable to psilocybin truffles, which remain the Netherlands' better-known legal psychedelic. |
| Canada | Controlled | LSD is a controlled substance under the Controlled Drugs and Substances Act, with no decriminalization or general therapeutic-access pathway. |
| Australia | Prohibited | LSD remains a Schedule 9 prohibited substance. Australia's 2023 therapeutic rescheduling covered MDMA and psilocybin only — LSD was not included. |
| Germany, France, Belgium, Denmark, Finland, Greece, Poland, Czech Republic, Mexico, Brazil, Jamaica, South Korea, South Africa, Malaysia, India, China, Russia, United Arab Emirates, New Zealand | Schedule I-equivalent | LSD is a controlled/prohibited substance under each country's national drug law, consistent with 1971 UN Convention scheduling obligations. No decriminalization or therapeutic exemption for LSD specifically is documented in any of these countries. |
1P-LSD and 1S-LSD are "research chemical" prodrugs of LSD — chemically modified versions that the body metabolizes into LSD itself or a closely related active compound. Neither is explicitly named on the DEA's Schedule I list. That does not make them legal to possess for human consumption: the same Federal Analogue Act (21 U.S.C. § 813) framing this site's DMT guide applies to 4-AcO-DMT applies here. The Analogue Act treats a substance "substantially similar" in chemical structure or pharmacological effect to a Schedule I drug as Schedule I when intended for human consumption. Because 1P-LSD and 1S-LSD are structurally close analogues of LSD (Schedule I) and metabolize into an active LSD-like compound, federal prosecution under this theory is legally viable, and several states have their own analogue acts that may independently apply. Vendor labeling such as "not for human consumption" does not provide legal protection where there is evidence of intended use.
Clinical trials. MM120 Voyage, Panorama, and Emerge are the primary open-to-enrollment pathways in the US and Europe. Check ClinicalTrials.gov for current site listings. Trial participants must meet GAD or MDD diagnostic criteria and typically must be medication-stable or willing to taper serotonergic medications under supervision.
Compassionate-use programs. Switzerland is the only country with an established physician-led pathway outside of trials.
Not available: there is no legal retreat model for LSD comparable to ayahuasca retreats, and LSD is not covered under Oregon’s or Colorado’s state-legal psilocybin frameworks.
The long duration of LSD means a therapeutic session is a half-day commitment; preparation sessions focus on set-and-setting and intention-setting, and integration sessions in the following week(s) help patients work with insights. This follows the general psychedelic integration model.
No. LSD (lysergic acid diethylamide) is a Schedule I controlled substance under federal law — meaning it has no currently accepted medical use and possession or distribution carries federal felony penalties. MindMed's MM120 (a pharmaceutical-grade LSD formulation) holds FDA Breakthrough Therapy Designation for generalized anxiety disorder, but that affects review speed, not current scheduling. An approved NDA would ultimately require DEA rescheduling.
Not for general adult use. Colorado's Natural Medicine Health Act (Prop 122, 2022) decriminalized personal-use possession of psilocybin, DMT, ibogaine, and mescaline for adults 21+, but LSD is not included in that list. LSD remains Schedule I under both federal and Colorado state law, with no therapeutic access program.
No. Oregon's Measure 109 licensed psilocybin services program covers psilocybin only — LSD is not included. Oregon's Measure 110 (2020) decriminalized personal-use possession of small amounts of all controlled substances, but that measure was partially rolled back by HB 4002 (2024), which restored misdemeanor penalties for personal-use possession. LSD possession remains a criminal offense in Oregon.
No. California has not passed any state-level decriminalization for LSD. Several cities (Oakland, San Francisco, Santa Cruz, Berkeley) have deprioritization resolutions for entheogenic plants and fungi — but LSD is a synthetic compound and is not covered by those resolutions. Possession of LSD in California is a criminal offense under both state and federal law.
Yes. LSD was legal and openly used in mainstream US psychiatric research from Sandoz's 1943 distribution of the compound to researchers until California became the first state to ban it in 1966. Federal law followed with the Controlled Substances Act of 1970, which placed LSD in Schedule I. During that roughly 25-year window, LSD was studied in thousands of published psychiatric reports covering alcoholism, anxiety, and end-of-life distress — the same research tradition MindMed's MM120 program is now revisiting under modern FDA trial standards.
No. LSD's legal status does not change based on dose. Whether it is a full 100–200 microgram therapeutic dose or a 10–20 microgram "microdose," LSD is a Schedule I controlled substance in every US state, and possession of any detectable amount carries the same federal felony exposure described above. No state's decriminalization law (including Colorado's Prop 122) includes LSD at any dose.
No. LSD (lysergic acid diethylamide) is a semi-synthetic compound derived from ergot fungus, while "magic mushrooms" refers to psilocybin-containing fungi such as <em>Psilocybe cubensis</em>. They act on the same serotonin receptor and produce broadly similar classic-psychedelic effects, but they are chemically distinct substances with different legal treatment in places like Oregon and Colorado, where psilocybin has a licensed therapeutic pathway that LSD does not share. See our <a href="/guides/psilocybin">psilocybin guide</a> for the mushroom-specific legal status.
Get LSD research & policy updates
New trials, FDA decisions, and legal changes for LSD — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.